Autolus Therapeutics plc (NASDAQ:AUTL) Shares Acquired by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC boosted its holdings in Autolus Therapeutics plc (NASDAQ:AUTL) by 27.4% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 4,300,000 shares of the company’s stock after buying an additional 925,000 shares during the period. Autolus Therapeutics makes up about 1.7% of Affinity Asset Advisors LLC’s investment portfolio, making the stock its 15th largest position. Affinity Asset Advisors LLC’s holdings in Autolus Therapeutics were worth $14,964,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Capstone Investment Advisors LLC acquired a new position in Autolus Therapeutics during the 4th quarter worth approximately $322,000. Bellevue Group AG acquired a new stake in shares of Autolus Therapeutics during the fourth quarter valued at about $322,000. Sierra Summit Advisors LLC purchased a new stake in shares of Autolus Therapeutics during the fourth quarter worth about $275,000. Perceptive Advisors LLC purchased a new position in Autolus Therapeutics in the fourth quarter valued at about $11,793,000. Finally, Perpetual Ltd grew its stake in Autolus Therapeutics by 8.2% during the 1st quarter. Perpetual Ltd now owns 2,234,515 shares of the company’s stock valued at $14,256,000 after purchasing an additional 169,784 shares in the last quarter. 72.83% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on AUTL shares. William Blair restated an “outperform” rating on shares of Autolus Therapeutics in a research note on Monday, June 3rd. Needham & Company LLC reiterated a “buy” rating and issued a $9.00 price target on shares of Autolus Therapeutics in a research note on Monday, June 17th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.70.

Autolus Therapeutics Trading Up 0.3 %

Shares of Autolus Therapeutics stock opened at $3.51 on Wednesday. Autolus Therapeutics plc has a 1-year low of $2.01 and a 1-year high of $7.45. The business’s fifty day moving average price is $4.05 and its two-hundred day moving average price is $4.36. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.09.

Autolus Therapeutics (NASDAQ:AUTL) last released its earnings results on Thursday, August 8th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). As a group, equities research analysts anticipate that Autolus Therapeutics plc will post -0.84 EPS for the current fiscal year.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.